Haematologica Reports 2005; 1(issue 9): 43-46
[prev][index][next]
Commentary on thrombotic and bleeding complications of
clinical trials of growth factor inhibitors
Kessler CM
Lombardi Comprehensive Cancer Center Georgetown University Medical
Center Washington, DC, USA
A number of naturally occurring and pathologic growth factors
have been identified in recent years to play pivotal roles in the
growth and metastastic potential of various cancers. As such, they
have emerged as interesting targets for the development of novel
therapeutic inhibitory agents and intervention strategies in the
cancer patient. Extensive preclinical and clinical trial results
with growth factor inhibitors have indicated that there is close
interplay between hemostasis, humoral anticoagulation, and
fibrinolytic mechanisms and the interference of these integral
growth factors in cancer cells.1 These interactions may
provide explanations for some of the thrombotic and hemorrhagic
complications associated with their administration. [>Read full article in PDF]
